Please assess the completion status of the following clinical trial:

Trial Title: Tysabri Observational Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Documented diagnosis of Relapsing Remitting Multiple Sclerosis~* The decision to treat with Tysabri must precede enrollment~* Patient must be a new Tysabri user, and must not have had more than 3 Tysabri infusions prior to enrollment~* Must have had at least one relapse in the previous year, and must satisfy locally approved therapeutic indications for Tysabri~Key Exclusion Criteria:~* History of Progressive Multifocal Leukoencephalopathy or other opportunistic infections, or an increased risk of opportunistic infections~* History of positive anti-Tysabri antibodies~* Concomitant Immunomodulatory or immunosuppressive therapy during therapy with Tysabri~* Patient immunocompromised at the time of enrollment~* Known active malignancy~* Women must not be breast feeding or pregnant, or planning to become pregnant (must use birth control unless surgically sterile)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tysabri (Type: None): According to the local prescribing information

Based on this trial design, predict the completion outcome and termination type (if applicable).